This company has been marked as potentially delisted and may not be actively trading.

Gracell Biotechnologies (GRCL) Competitors

GRCL vs. DFTX, HYPD, LIAN, PHXM, and ADIL

Should you be buying Gracell Biotechnologies stock or one of its competitors? The main competitors of Gracell Biotechnologies include Definium Therapeutics (DFTX), Hyperion DeFi (HYPD), LianBio (LIAN), PHAXIAM Therapeutics (PHXM), and Adial Pharmaceuticals (ADIL). These companies are all part of the "biotechnology" industry.

How does Gracell Biotechnologies compare to Definium Therapeutics?

Gracell Biotechnologies (NASDAQ:GRCL) and Definium Therapeutics (NASDAQ:DFTX) are both medical companies, but which is the better investment? We will compare the two businesses based on the strength of their earnings, analyst recommendations, valuation, institutional ownership, media sentiment, dividends, risk and profitability.

: Gracell Biotechnologies has higher revenue and earnings than Definium Therapeutics. Definium Therapeutics is trading at a lower price-to-earnings ratio than Gracell Biotechnologies, indicating that it is currently the more affordable of the two stocks.
Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Gracell Biotechnologies $60K 12,415.83 -$88.08M -$1.05 N/A
Definium Therapeutics N/A N/A -$183.79M -$2.13 N/A
: Gracell Biotechnologies has a beta of -0.33, meaning that its share price is 133% less volatile than the S&P 500. Comparatively, Definium Therapeutics has a beta of 2.37, meaning that its share price is 137% more volatile than the S&P 500.
: Definium Therapeutics has a consensus target price of $38.00, suggesting a potential upside of 69.64%. Given Definium Therapeutics' stronger consensus rating and higher probable upside, analysts plainly believe Definium Therapeutics is more favorable than Gracell Biotechnologies.
Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Gracell Biotechnologies
0 Sell rating(s)
0 Hold rating(s)

0 Buy rating(s)

0 Strong Buy rating(s)
0.00
Definium Therapeutics
1 Sell rating(s)

0 Hold rating(s)

11 Buy rating(s)

3 Strong Buy rating(s)
3.07
: Gracell Biotechnologies' return on equity of -37.40% beat Definium Therapeutics' return on equity.
Company Net Margins Return on Equity Return on Assets
Gracell Biotechnologies N/A -37.40% -31.24%
Definium Therapeutics N/A -82.07% -58.73%
: 27.9% of Definium Therapeutics shares are held by institutional investors. 28.0% of Gracell Biotechnologies shares are held by company insiders. Comparatively, 2.3% of Definium Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.
: In the previous week, Definium Therapeutics had 5 more articles in the media than Gracell Biotechnologies. MarketBeat recorded 5 mentions for Definium Therapeutics and 0 mentions for Gracell Biotechnologies. Definium Therapeutics' average media sentiment score of 1.02 beat Gracell Biotechnologies' score of 0.00 indicating that Definium Therapeutics is being referred to more favorably in the news media.
Company Overall Sentiment
Gracell Biotechnologies Neutral
Definium Therapeutics Positive

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Gracell Biotechnologies	$60K	12,415.83	-$88.08M	-$1.05	N/A
Definium Therapeutics	N/A	N/A	-$183.79M	-$2.13	N/A

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Gracell Biotechnologies	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00
Definium Therapeutics	1 Sell rating(s)	0 Hold rating(s)	11 Buy rating(s)	3 Strong Buy rating(s)	3.07

Company	Net Margins	Return on Equity	Return on Assets
Gracell Biotechnologies	N/A	-37.40%	-31.24%
Definium Therapeutics	N/A	-82.07%	-58.73%

Company	Overall Sentiment
Gracell Biotechnologies	Neutral
Definium Therapeutics	Positive

Summary

Definium Therapeutics beats Gracell Biotechnologies on 8 of the 15 factors compared between the two stocks.

How does Gracell Biotechnologies compare to Hyperion DeFi?

Gracell Biotechnologies (NASDAQ:GRCL) and Hyperion DeFi (NASDAQ:HYPD) are both small-cap medical companies, but which is the better stock? We will contrast the two companies based on the strength of their institutional ownership, analyst recommendations, profitability, risk, dividends, earnings, media sentiment and valuation.

: Hyperion DeFi has higher revenue and earnings than Gracell Biotechnologies. Gracell Biotechnologies is trading at a lower price-to-earnings ratio than Hyperion DeFi, indicating that it is currently the more affordable of the two stocks.
Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Gracell Biotechnologies $60K 12,415.83 -$88.08M -$1.05 N/A
Hyperion DeFi $813.46K 65.40 -$45.31M -$11.80 N/A
: Gracell Biotechnologies has a beta of -0.33, indicating that its share price is 133% less volatile than the S&P 500. Comparatively, Hyperion DeFi has a beta of 2.57, indicating that its share price is 157% more volatile than the S&P 500.
: Hyperion DeFi has a consensus target price of $5.88, suggesting a potential upside of 25.80%. Given Hyperion DeFi's stronger consensus rating and higher probable upside, analysts plainly believe Hyperion DeFi is more favorable than Gracell Biotechnologies.
Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Gracell Biotechnologies
0 Sell rating(s)
0 Hold rating(s)

0 Buy rating(s)

0 Strong Buy rating(s)
0.00
Hyperion DeFi
2 Sell rating(s)

0 Hold rating(s)

1 Buy rating(s)

1 Strong Buy rating(s)
2.25
: Gracell Biotechnologies' return on equity of -37.40% beat Hyperion DeFi's return on equity.
Company Net Margins Return on Equity Return on Assets
Gracell Biotechnologies N/A -37.40% -31.24%
Hyperion DeFi N/A -129.97% -92.39%
: 25.8% of Hyperion DeFi shares are held by institutional investors. 28.0% of Gracell Biotechnologies shares are held by company insiders. Comparatively, 10.9% of Hyperion DeFi shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.
: In the previous week, Hyperion DeFi had 4 more articles in the media than Gracell Biotechnologies. MarketBeat recorded 4 mentions for Hyperion DeFi and 0 mentions for Gracell Biotechnologies. Hyperion DeFi's average media sentiment score of 0.66 beat Gracell Biotechnologies' score of 0.00 indicating that Hyperion DeFi is being referred to more favorably in the news media.
Company Overall Sentiment
Gracell Biotechnologies Neutral
Hyperion DeFi Positive

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Gracell Biotechnologies	$60K	12,415.83	-$88.08M	-$1.05	N/A
Hyperion DeFi	$813.46K	65.40	-$45.31M	-$11.80	N/A

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Gracell Biotechnologies	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00
Hyperion DeFi	2 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	1 Strong Buy rating(s)	2.25

Company	Net Margins	Return on Equity	Return on Assets
Gracell Biotechnologies	N/A	-37.40%	-31.24%
Hyperion DeFi	N/A	-129.97%	-92.39%

Company	Overall Sentiment
Gracell Biotechnologies	Neutral
Hyperion DeFi	Positive

Summary

Hyperion DeFi beats Gracell Biotechnologies on 11 of the 16 factors compared between the two stocks.

How does Gracell Biotechnologies compare to LianBio?

Gracell Biotechnologies (NASDAQ:GRCL) and LianBio (NASDAQ:LIAN) are both small-cap medical companies, but which is the better stock? We will contrast the two companies based on the strength of their institutional ownership, analyst recommendations, profitability, risk, dividends, earnings, media sentiment and valuation.

: Gracell Biotechnologies has higher revenue and earnings than LianBio. Gracell Biotechnologies is trading at a lower price-to-earnings ratio than LianBio, indicating that it is currently the more affordable of the two stocks.
Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Gracell Biotechnologies $60K 12,415.83 -$88.08M -$1.05 N/A
LianBio N/A N/A -$110.29M -$0.81 N/A
: Gracell Biotechnologies has a beta of -0.33, meaning that its stock price is 133% less volatile than the S&P 500. Comparatively, LianBio has a beta of 0.23, meaning that its stock price is 77% less volatile than the S&P 500.
: LianBio's return on equity of -33.17% beat Gracell Biotechnologies' return on equity.
Company Net Margins Return on Equity Return on Assets
Gracell Biotechnologies N/A -37.40% -31.24%
LianBio N/A -33.17% -30.19%
: 74.8% of LianBio shares are owned by institutional investors. 28.0% of Gracell Biotechnologies shares are owned by company insiders. Comparatively, 7.6% of LianBio shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.
: In the previous week, Gracell Biotechnologies' average media sentiment score of 0.00 equaled LianBio'saverage media sentiment score.
Company Overall Sentiment
Gracell Biotechnologies Neutral
LianBio Neutral

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Gracell Biotechnologies	$60K	12,415.83	-$88.08M	-$1.05	N/A
LianBio	N/A	N/A	-$110.29M	-$0.81	N/A

Company	Net Margins	Return on Equity	Return on Assets
Gracell Biotechnologies	N/A	-37.40%	-31.24%
LianBio	N/A	-33.17%	-30.19%

Company	Overall Sentiment
Gracell Biotechnologies	Neutral
LianBio	Neutral

Summary

LianBio beats Gracell Biotechnologies on 6 of the 9 factors compared between the two stocks.

How does Gracell Biotechnologies compare to PHAXIAM Therapeutics?

Gracell Biotechnologies (NASDAQ:GRCL) and PHAXIAM Therapeutics (NASDAQ:PHXM) are both small-cap medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their institutional ownership, analyst recommendations, profitability, valuation, risk, earnings, media sentiment and dividends.

: Gracell Biotechnologies has a beta of -0.33, suggesting that its stock price is 133% less volatile than the S&P 500. Comparatively, PHAXIAM Therapeutics has a beta of 2.35, suggesting that its stock price is 135% more volatile than the S&P 500.
: PHAXIAM Therapeutics has lower revenue, but higher earnings than Gracell Biotechnologies.
Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Gracell Biotechnologies $60K 12,415.83 -$88.08M -$1.05 N/A
PHAXIAM Therapeutics N/A N/A -$240K N/A N/A
: PHAXIAM Therapeutics' return on equity of 0.00% beat Gracell Biotechnologies' return on equity.
Company Net Margins Return on Equity Return on Assets
Gracell Biotechnologies N/A -37.40% -31.24%
PHAXIAM Therapeutics N/A N/A N/A
: In the previous week, Gracell Biotechnologies' average media sentiment score of 0.00 equaled PHAXIAM Therapeutics'average media sentiment score.
Company Overall Sentiment
Gracell Biotechnologies Neutral
PHAXIAM Therapeutics Neutral
: 0.4% of PHAXIAM Therapeutics shares are owned by institutional investors. 28.0% of Gracell Biotechnologies shares are owned by insiders. Comparatively, 1.9% of PHAXIAM Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Gracell Biotechnologies	$60K	12,415.83	-$88.08M	-$1.05	N/A
PHAXIAM Therapeutics	N/A	N/A	-$240K	N/A	N/A

Company	Net Margins	Return on Equity	Return on Assets
Gracell Biotechnologies	N/A	-37.40%	-31.24%
PHAXIAM Therapeutics	N/A	N/A	N/A

Company	Overall Sentiment
Gracell Biotechnologies	Neutral
PHAXIAM Therapeutics	Neutral

Summary

PHAXIAM Therapeutics beats Gracell Biotechnologies on 5 of the 7 factors compared between the two stocks.

How does Gracell Biotechnologies compare to Adial Pharmaceuticals?

Gracell Biotechnologies (NASDAQ:GRCL) and Adial Pharmaceuticals (NASDAQ:ADIL) are both small-cap medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their institutional ownership, analyst recommendations, profitability, valuation, risk, earnings, media sentiment and dividends.

: Gracell Biotechnologies has a beta of -0.33, indicating that its stock price is 133% less volatile than the S&P 500. Comparatively, Adial Pharmaceuticals has a beta of 1.27, indicating that its stock price is 27% more volatile than the S&P 500.
: Adial Pharmaceuticals has lower revenue, but higher earnings than Gracell Biotechnologies. Gracell Biotechnologies is trading at a lower price-to-earnings ratio than Adial Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.
Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Gracell Biotechnologies $60K 12,415.83 -$88.08M -$1.05 N/A
Adial Pharmaceuticals N/A N/A -$7.98M -$18.75 N/A
: Gracell Biotechnologies' return on equity of -37.40% beat Adial Pharmaceuticals' return on equity.
Company Net Margins Return on Equity Return on Assets
Gracell Biotechnologies N/A -37.40% -31.24%
Adial Pharmaceuticals N/A -182.34% -141.27%
: Adial Pharmaceuticals has a consensus price target of $22.75, indicating a potential upside of 1,321.88%. Given Adial Pharmaceuticals' stronger consensus rating and higher possible upside, analysts clearly believe Adial Pharmaceuticals is more favorable than Gracell Biotechnologies.
Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Gracell Biotechnologies
0 Sell rating(s)
0 Hold rating(s)

0 Buy rating(s)

0 Strong Buy rating(s)
0.00
Adial Pharmaceuticals
1 Sell rating(s)

1 Hold rating(s)

1 Buy rating(s)

0 Strong Buy rating(s)
2.00
: In the previous week, Adial Pharmaceuticals had 1 more articles in the media than Gracell Biotechnologies. MarketBeat recorded 1 mentions for Adial Pharmaceuticals and 0 mentions for Gracell Biotechnologies. Gracell Biotechnologies' average media sentiment score of 0.00 equaled Adial Pharmaceuticals'average media sentiment score.
Company Overall Sentiment
Gracell Biotechnologies Neutral
Adial Pharmaceuticals Neutral
: 16.4% of Adial Pharmaceuticals shares are held by institutional investors. 28.0% of Gracell Biotechnologies shares are held by company insiders. Comparatively, 1.9% of Adial Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Gracell Biotechnologies	$60K	12,415.83	-$88.08M	-$1.05	N/A
Adial Pharmaceuticals	N/A	N/A	-$7.98M	-$18.75	N/A

Company	Net Margins	Return on Equity	Return on Assets
Gracell Biotechnologies	N/A	-37.40%	-31.24%
Adial Pharmaceuticals	N/A	-182.34%	-141.27%

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Gracell Biotechnologies	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00
Adial Pharmaceuticals	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

Company	Overall Sentiment
Gracell Biotechnologies	Neutral
Adial Pharmaceuticals	Neutral

Summary

Adial Pharmaceuticals beats Gracell Biotechnologies on 8 of the 13 factors compared between the two stocks.

Get Gracell Biotechnologies News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding GRCL and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

GRCL vs. The Competition

Export

Metric	Gracell Biotechnologies	Biotechnology Industry	Medical Sector	NASDAQ Exchange
Market Cap	$744.95M	$446.06M	$6.25B	$11.87B
Dividend Yield	N/A	3.86%	2.73%	5.21%
P/E Ratio	-9.76	4.19	29.04	28.47
Price / Sales	12,415.83	6,879.71	476.61	60.94
Price / Cash	N/A	13.13	27.62	36.52
Price / Book	3.47	77.74	9.67	6.67
Net Income	-$88.08M	-$96.07M	$3.55B	$332.53M

Gracell Biotechnologies Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
GRCL Gracell Biotechnologies	N/A	$10.25 flat	N/A	N/A	$744.95M	$60K	N/A	314
DFTX Definium Therapeutics	3.8526 of 5 stars	$21.70 -0.8%	$38.00 +75.1%	N/A	$2.16B	N/A	N/A	40	Positive News Upcoming Earnings
HYPD Hyperion DeFi	2.9441 of 5 stars	$4.18 +3.7%	$5.88 +40.6%	N/A	$47.62M	$810K	N/A	40	News Coverage Gap Up
LIAN LianBio	N/A	$0.12 -0.4%	N/A	N/A	$13.13M	N/A	N/A	110
PHXM PHAXIAM Therapeutics	N/A	$3.10 flat	N/A	N/A	$10.58M	N/A	N/A	49

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:GRCL) was last updated on 5/5/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Gracell Biotechnologies (GRCL) Competitors

GRCL vs. DFTX, HYPD, LIAN, PHXM, and ADIL

How does Gracell Biotechnologies compare to Definium Therapeutics?

Summary

How does Gracell Biotechnologies compare to Hyperion DeFi?

Summary

How does Gracell Biotechnologies compare to LianBio?

Summary

How does Gracell Biotechnologies compare to PHAXIAM Therapeutics?

Summary

How does Gracell Biotechnologies compare to Adial Pharmaceuticals?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

GRCL vs. The Competition

Gracell Biotechnologies Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Gracell Biotechnologies (GRCL) Competitors

GRCL vs. DFTX, HYPD, LIAN, PHXM, and ADIL

How does Gracell Biotechnologies compare to Definium Therapeutics?

Summary

How does Gracell Biotechnologies compare to Hyperion DeFi?

Summary

How does Gracell Biotechnologies compare to LianBio?

Summary

How does Gracell Biotechnologies compare to PHAXIAM Therapeutics?

Summary

How does Gracell Biotechnologies compare to Adial Pharmaceuticals?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

GRCL vs. The Competition

Gracell Biotechnologies Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools